Genentech team does some cutting-edge work on a new class of antibiotics — here's why that's important
One of my many mantras about R&D is that Big Pharma largely bowed out of basic antibiotic research to focus on more profitable ventures — leaving the field mostly to smaller biotech players which have been fielding some of the new players with marginal commercial potential.
And now Genentech wants to spoil that meme.
A discovery team at Roche’s big biotech operation has been working on a new antibiotic for gram-negative bacteria. And now they have a preclinical candidate they say has real potential to go on to become the first breakthrough in that field in more than half a century.
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
